RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SUZUKI K
Collezione AOU Città della Salute di Torino

Items : 3

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029.

2024
AOU Città della Salute di Torino

Dimopoulos MA; Voorhees PM; Schjesvold F; Cohen YC; Hungria V; Sandhu I; Lindsay J; Baker RI; Suzuki K; Kosugi H; Levin MD; Beksac M; Stockerl-Goldstein K; Oriol A; Mikala G; Garate G; Theunissen K; Spicka I; Mylin AK; Bringhen S; Uttervall K; Pula B; Medvedova E; Cowan AJ; Moreau P; Mateos MV; Goldschmidt H; Ahmadi T; Sha L; et alii...

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

2019
AOU Città della Salute di Torino

Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;

ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. in Scientific reports / Sci Rep. 2017 Feb 8;7:42170. doi: 10.1038/srep42170.

2017
AOU Città della Salute di Torino

Zhang R; Knapp M; Suzuki K; Kajioka D; Schmidt JM; Winkler J; Yilmaz Ö; Pleschka M; Cao J; Kockum CC; Barker G; Holmdahl G; Beaman G; Keene D; Woolf AS; Cervellione RM; Cheng W; Wilkins S; Gearhart JP; Sirchia F; Di Grazia M; Ebert AK; Rösch W; Ellinger J; Jenetzky E; Zwink N; Feitz WF; Marcelis C; Schumacher J; et alii...